Fechner H, Haack A, Wang H, Wang X, Eizema K, Pauschinger M, Schoemaker R, Veghel R, Houtsmuller A, Schultheiss H P, Lamers J, Poller W
Department of Cardiology and Pneumology, University Hospital Benjamin Franklin, Freie Universität, Berlin, Germany.
Gene Ther. 1999 Sep;6(9):1520-35. doi: 10.1038/sj.gt.3301030.
Recombinant adenoviral vectors are broadly applied in gene therapy protocols. However, adenovector-mediated gene transfer has limitations in vivo. One of these is the low gene transfer rate into organs other than the liver after systemic intravenous vector injection. Local direct injection into the target organ has been used as one possible solution, but increases necessary equipment and methodology and is traumatic to the target. Wild-type adenovirus infection as well as adenovector-mediated gene transfer depends on virus interaction with the Coxsackie adenovirus receptor (CAR) mediating virus attachment to the cell surface, and on interaction with alphavbeta3 and alphavbeta5 integrins mediating virus entry into the cell. In order to assess the receptor-associated potential of different tissues to act as adenovector targets, we have therefore determined CAR and alphav-integrin expression in multiple organs from different species. In addition, we have newly determined several human, rat, pig and dog CAR-mRNA sequences. Sequence comparison and structural analyses of known and of newly determined sequences suggests a potential adenovirus binding site between amino acids 29 and 128 of the CAR. With respect to the virus receptor expression patterns we found that CAR-mRNA expression was extremely variable between different tissues, with the highest levels in the liver, whereas alphav-integrin expression was far more homogenous among different organs. Both CAR and alphav-integrin showed similar expression patterns among different species. There was no correlation, however, between the adenovector expression patterns after intravenous, intracardiac and aortic root injection, respectively, and the virus receptor patterns. In summary, many organs carry both receptors required to make them potential adenovector targets. In sharp contrast, their actual targeting clearly indicates that adenovirus receptor expression is necessary but not sufficient for vector transfer after systemic injection. The apparently very important role of anatomical barriers, in particular the endothelium, requires close attention when developing non-traumatic, organ-specific gene therapy protocols.
重组腺病毒载体广泛应用于基因治疗方案中。然而,腺病毒载体介导的基因转移在体内存在局限性。其中之一是全身静脉注射载体后,除肝脏外的其他器官基因转移率较低。局部直接注射到靶器官已被用作一种可能的解决方案,但增加了所需的设备和方法,并且对靶器官有创伤。野生型腺病毒感染以及腺病毒载体介导的基因转移取决于病毒与柯萨奇腺病毒受体(CAR)的相互作用,介导病毒附着于细胞表面,以及与αvβ3和αvβ5整合素的相互作用,介导病毒进入细胞。因此,为了评估不同组织作为腺病毒载体靶标的受体相关潜力,我们测定了来自不同物种多个器官中CAR和αv整合素的表达。此外,我们新测定了几种人、大鼠、猪和狗的CAR-mRNA序列。已知序列和新测定序列的序列比较及结构分析表明,CAR氨基酸29至128之间存在潜在的腺病毒结合位点。关于病毒受体表达模式,我们发现不同组织之间CAR-mRNA表达差异极大,肝脏中水平最高,而αv整合素表达在不同器官中更为均匀。CAR和αv整合素在不同物种中表现出相似的表达模式。然而,分别经静脉、心内和主动脉根部注射后的腺病毒载体表达模式与病毒受体模式之间没有相关性。总之,许多器官都携带使它们成为潜在腺病毒载体靶标的两种受体。与之形成鲜明对比的是,它们的实际靶向情况清楚地表明,腺病毒受体表达对于全身注射后的载体转移是必要的,但并不充分。在制定非创伤性、器官特异性基因治疗方案时,解剖屏障尤其是内皮的明显非常重要的作用需要密切关注。